Solicitation of Information on the Use of Tryptamine-Related Compounds, 44314-44315 [E6-12599]
Download as PDF
<![CDATA[
gechino on PROD1PC61 with NOTICES
44314
Federal Register / Vol. 71, No. 150 / Friday, August 4, 2006 / Notices
information are encouraged. Your
comments should address one or more
of the following four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agencies
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of this information
collection:
(1) Type of Information Collection:
Extension, without change, of a
currently approved collection.
(2) Title of the Form/Collection:
Annuity Broker Qualification
Declaration Form.
(3) Agency form number, if any, and
the applicable component of the
Department of Justice sponsoring the
collection: Department of Justice, Civil
Division.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: Individuals. This
declaration is to be submitted annually
to determine whether a broker meets the
qualifications to be listed as an annuity
broker pursuant to Section 11015(b) of
Public Law 107–273.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 400
respondents will complete the form
annually within approximately 1 hour.
(6) An estimate of the total public
burden (in hours) associated with the
collection: There are an estimated 400
total annual burden hours associated
with this collection.
If additional information is required
contact: Lynn Bryant, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Patrick Henry Building,
Suite 1600, 601 D Street NW.,
Washington, DC 20530.
VerDate Aug<31>2005
22:39 Aug 03, 2006
Jkt 208001
Dated: August 1, 2006.
Lynn Bryant,
Department Clearance Officer, Department of
Justice.
[FR Doc. 06–6697 Filed 8–3–06; 8:45 am]
BILLING CODE 4410–12–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–273N]
Solicitation of Information on the Use
of Tryptamine-Related Compounds
Drug Enforcement
Administration (DEA), Justice.
ACTION: Notice of request for
information.
AGENCY:
SUMMARY: The DEA is soliciting
information on substances that are
related in chemical structure to
tryptamine (see SUPPLEMENTARY
INFORMATION). The Controlled
Substances Act (CSA), in Title 21 of the
United States Code (U.S.C. 812(c)
Schedule I (Title 21 of the Code of
Federal Regulations (CFR 1308.11(d)),
lists certain tryptamines as Schedule I
controlled substances. Some
tryptamines that are not controlled
under the CSA produce central nervous
system effects that are similar to
tryptamines that are controlled under
the CSA. DEA is requesting information
to help determine the impact on
business if these substances were to be
placed under control in the CSA.
DATES: Written comments must be
postmarked, and electronic comments
must be sent, on or before October 3,
2006.
To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–273N’’ on all written and
electronic correspondence. Written
comments being sent via regular mail
should be sent to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, Washington, DC 20537,
Attention: DEA Federal Register
Representative/ODL. Written comments
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, VA 22301. Comments may
be directly sent to DEA electronically by
sending an electronic message to
dea.diversion.policy@usdoj.gov.
Comments may also be sent
electronically through https://
www.regulations.gov using the
electronic comment form provided on
that site. An electronic copy of this
ADDRESSES:
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
document is also available at the https://
www.regulations.gov Web site. DEA will
accept attachments to electronic
comments in Microsoft Word,
WordPerfect, Adobe PDF, or Excel file
formats only. DEA will not accept any
file format other than those specifically
listed here.
FOR FURTHER INFORMATION CONTACT:
Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537; Telephone:
(202) 307–7183.
SUPPLEMENTARY INFORMATION:
Tryptamine is a compound in which the
chemical structure can be described as
indole substituted at the three position
with an 2-aminoethyl chain. Although
tryptamine itself is not a controlled
substance, its chemical structure
constitutes the skeletal makeup of
tryptamines listed in Schedule I of the
CSA, which are classified as
hallucinogenic substances.
Tryptamine is sometimes substituted
on the indole ring or the 2-aminoethyl
chain or both with various substituents.
Title 21 CFR 1308.11(d) lists specific
substituted tryptamines in Schedule I.
Also included in Schedule I are the
salts, isomers, and salts of isomers of the
listed tryptamines. The term isomer, as
used in this section, means the optical,
geometric, and positional isomers.
Individuals have published detailed
methods of synthesis for substituted
tryptamines and have reported
pharmacological effects based on user
experiences. Law enforcement
personnel encounter such tryptamines,
but because they are substituted
differently than those listed or described
in the CSA, they are not subject to direct
control in Schedule I. However, some of
these substances can be treated as
Schedule I controlled substance
analogues if intended for human
consumption (21 U.S.C. 802(32); § 813).
DEA is soliciting information on (1)
The commercial uses for tryptamines,
(2) activities involving research and
development, (3) tryptamines as
intermediates or analytical standards,
(4) import and domestic sources for
tryptamines, and (5) any planned or
anticipated uses for tryptamines. DEA
invites interested persons to provide
any information on the uses of
tryptamines in industry, academia,
research and development, or other
applications. Both quantitative and
qualitative information is sought.
Although information is requested for
all tryptamine substances regardless of
substitutions, DEA is particularly
interested in tryptamines that meet one
E:\FR\FM\04AUN1.SGM
04AUN1
Federal Register / Vol. 71, No. 150 / Friday, August 4, 2006 / Notices
gechino on PROD1PC61 with NOTICES
or more of the following conditions: (a)
Has a secondary or tertiary amine
formed by the substitution on the
nitrogen atom of the 2-aminoethyl chain
by various alkyl groups, whether in
chain or ring form (for example, Nalkyltryptamine, N,N-dialkyltryptamine,
N,N-tetramethylenetryptamine), (b) has
an alkyl substitution on the alpha
position of the 2-aminoethyl chain, and/
or (c) has substituents on the indole ring
system, including, but not restricted to,
various alkyl chains, halogens,
hydroxyl, alkoxy, acetyl, or alkylthio
groups, at one or more positions except
the one (indole nitrogen) position. DEA
is especially interested in learning of the
uses of the following tryptamines.
2-alpha-dimethyltryptamine
4-hydroxy-N,N-diisopropyltryptamine
4-hydroxy-N,N-dipropyltryptamine
4-hydroxy-N,N-tetramethylenetryptamine
4-hydroxy-N-isopropyl-N-methyltryptamine
4-hydroxy-N-methyl-N-propyltryptamine
5,6-dimethoxy-N-isopropyl-Nmethyltryptamine
5-methoxy-alpha,N-dimethyltryptamine
5-methoxy-alpha-methyltryptamine
5-methoxy-N,N-dimethyl-2methyltryptamine
5-methoxy-N,N-dimethyltryptamine
5-methoxy-N,N-tetramethylenetryptamine
5-methoxy-N-methyltryptamine
6-methoxy-1-methyl-1,2,3,4-tetrahydro-betacarboline
7-methoxy-1-methyl-1,2,3,4-tetrahydro-betacarboline
9,10-didehydro-6-allyl-N,N-diethylergoline8-beta-carboxamide
9,10-didehydro-6-propyl-N,Ndiethylergoline-8-beta-carboxamide
9,10-didehydro-N,N,6-triethylergoline-8-betacarboxamide
alpha,N-dimethyltryptamine
N,N-dibutyltryptamine
N,N-dibutyl-4-hydroxytryptamine
N,N-diethyl-2-methyltryptamine
4-hydroxy-N,N-diethyltryptamine
N,N-diethyl-5-methoxytryptamine
N,N-diisopropyl-4,5methylenedioxytryptamine
N,N-diisopropyl-5,6methylenedioxytryptamine
N,N-diisopropyltryptamine
N,N-dimethyl-2-methyltryptamine
N,N-dimethyl-4,5-methylenedioxytryptamine
N,N-dimethyl-4-hydroxytryptamine
N,N-dimethyl-5,6-methylenedioxytryptamine
N,N-dimethyl-5-methylthiotryptamine
N,N-dipropyltryptamine
N,N-tetramethylenetryptamine
N-butyl-N-methyltryptamine
N-ethyl-4-hydroxy-N-methyltryptamine
N-ethyl-N-isopropyltryptamine
N-ethyltryptamine
4-methoxy-N-methyl-N-isopropyltryptamine
5-methoxy-N-methyl-N-isopropyltryptamine
N-isopropyl-N-methyl-5,6methylenedioxytryptamine
N-isopropyl-N-methyltryptamine
N-methyltryptamine
4-acetoxy-N-methyl-N-isopropyltryptamine
4-acetoxy-N,N-diisopropyltryptamine
4-acetoxy-N,N-dipropyltryptamine
VerDate Aug<31>2005
22:39 Aug 03, 2006
Jkt 208001
4-acetoxy-N,N-diethyltryptamine
5-methoxy-N,N-diallyltryptamine
5-methoxy-N-monoallyltryptamine
5-methoxy-N-methyl-N-isopropyltryptamin
N-methyl-N-isopropyltryptamine
4-hydroxy-N,N-diethyltryptamine
5-methoxy-N,N-diethyltryptamine
Such information may be submitted to
the Drug and Chemical Evaluation
Section and is requested by October 3,
2006. Information designated as
confidential or proprietary will be
treated accordingly. Confidential
business information is protected from
disclosure under Exemption 4 of the
Freedom of Information Act, 5 U.S.C.
552(b)(4)(FOIA) and the Department of
Justice procedures set forth in 28 CFR
16.8.
Dated: July 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control.
[FR Doc. E6–12599 Filed 8–3–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
[TA–W–58,882]
APA Enterprises, Inc., Aberdeen, SD;
Affirmative Determinations for Worker
Adjustment Assistance and Alternative
Trade Adjustment Assistance;
Correction
This notice rescinds the notice of
certification of eligibility to apply for
Alternative Trade Adjustment
Assistance applicable to TA–W–58,882,
which was published in the Federal
Register on April 17, 2006 (71 FR
19753–19756) in FR Document E6–
5658.
This rescinds the certification of
eligibility for workers of TA–W–58,882,
to apply for Alternative Trade
Adjustment Assistance and confirms
eligibility to apply for Worker
Adjustment Assistance as identified on
page 19755 in the first column, the
second TA–W–number listed.
The Department appropriately
published in the Federal Register April
17, 2006, page 19755, under the notice
of Negative Determinations for
Alternative Trade Adjustment
Assistance, the denial of eligibility
applicable to workers of TA–W–58,882.
The notice appears on page 19755 in the
third column, the thirteenth TA–W–
number listed.
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
44315
Signed in Washington, DC, this 28th day of
July 2006.
Erica R. Cantor,
Director, Division of Trade Adjustment
Assistance.
[FR Doc. E6–12614 Filed 8–3–06; 8:45 am]
BILLING CODE 4510–30–P
DEPARTMENT OF LABOR
Employment and Training
Administration
[TA–W–58,819]
Bentwood Furniture, Inc., Grants Pass,
OR; Affirmative Determinations for
Worker Adjustment Assistance and
Alternative Trade Adjustment
Assistance; Correction
This notice rescinds the notice of
certification of eligibility to apply for
Alternative Trade Adjustment
Assistance applicable to TA–W–58,819,
which was published in the Federal
Register on April 13, 2006 (71 FR
This rescinds the certification of
eligibility for workers of TA–W–58,819,
to apply for Alternative Trade
Adjustment Assistance and confirms
eligibility to apply for Worker
Adjustment Assistance as identified on
page 19209 in the first column, the
sixteenth TA–W–number listed.
The Department appropriately
published in the Federal Register April
13, 2006, page 19210, under the notice
of Negative Determinations for
Alternative Trade Adjustment
Assistance, the denial of eligibility
applicable to workers of TA–W–58,819.
The notice appears on page 19210 in the
third column, the fifth TA–W–number
listed.
Signed in Washington, DC, this 28th day of
July 2006.
Erica R. Cantor,
Director, Division of Trade Adjustment
Assistance.
[FR Doc. E6–12619 Filed 8–3–06; 8:45 am]
BILLING CODE 4510–30–P
DEPARTMENT OF LABOR
Employment and Training
Administration
[TA–W–58,759]
Buckingham Galleries, New Hartford,
CT; Affirmative Determinations for
Worker Adjustment Assistance and
Alternative Trade Adjustment
Assistance; Correction
This notice rescinds the notice of
certification of eligibility to apply for
Alternative Trade Adjustment
E:\FR\FM\04AUN1.SGM
04AUN1
]]>Agencies
[Federal Register Volume 71, Number 150 (Friday, August 4, 2006)]
[Notices]
[Pages 44314-44315]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-12599]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-273N]
Solicitation of Information on the Use of Tryptamine-Related
Compounds
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of request for information.
-----------------------------------------------------------------------
SUMMARY: The DEA is soliciting information on substances that are
related in chemical structure to tryptamine (see SUPPLEMENTARY
INFORMATION). The Controlled Substances Act (CSA), in Title 21 of the
United States Code (U.S.C. 812(c) Schedule I (Title 21 of the Code of
Federal Regulations (CFR 1308.11(d)), lists certain tryptamines as
Schedule I controlled substances. Some tryptamines that are not
controlled under the CSA produce central nervous system effects that
are similar to tryptamines that are controlled under the CSA. DEA is
requesting information to help determine the impact on business if
these substances were to be placed under control in the CSA.
DATES: Written comments must be postmarked, and electronic comments
must be sent, on or before October 3, 2006.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-273N'' on all written and electronic correspondence.
Written comments being sent via regular mail should be sent to the
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL. Written comments sent via express
mail should be sent to DEA Headquarters, Attention: DEA Federal
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria,
VA 22301. Comments may be directly sent to DEA electronically by
sending an electronic message to dea.diversion.policy@usdoj.gov.
Comments may also be sent electronically through https://
www.regulations.gov using the electronic comment form provided on that
site. An electronic copy of this document is also available at the
https://www.regulations.gov Web site. DEA will accept attachments to
electronic comments in Microsoft Word, WordPerfect, Adobe PDF, or Excel
file formats only. DEA will not accept any file format other than those
specifically listed here.
FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section, Office of Diversion Control, Drug
Enforcement Administration, Washington, DC 20537; Telephone: (202) 307-
7183.
SUPPLEMENTARY INFORMATION: Tryptamine is a compound in which the
chemical structure can be described as indole substituted at the three
position with an 2-aminoethyl chain. Although tryptamine itself is not
a controlled substance, its chemical structure constitutes the skeletal
makeup of tryptamines listed in Schedule I of the CSA, which are
classified as hallucinogenic substances.
Tryptamine is sometimes substituted on the indole ring or the 2-
aminoethyl chain or both with various substituents. Title 21 CFR
1308.11(d) lists specific substituted tryptamines in Schedule I. Also
included in Schedule I are the salts, isomers, and salts of isomers of
the listed tryptamines. The term isomer, as used in this section, means
the optical, geometric, and positional isomers.
Individuals have published detailed methods of synthesis for
substituted tryptamines and have reported pharmacological effects based
on user experiences. Law enforcement personnel encounter such
tryptamines, but because they are substituted differently than those
listed or described in the CSA, they are not subject to direct control
in Schedule I. However, some of these substances can be treated as
Schedule I controlled substance analogues if intended for human
consumption (21 U.S.C. 802(32); Sec. 813).
DEA is soliciting information on (1) The commercial uses for
tryptamines, (2) activities involving research and development, (3)
tryptamines as intermediates or analytical standards, (4) import and
domestic sources for tryptamines, and (5) any planned or anticipated
uses for tryptamines. DEA invites interested persons to provide any
information on the uses of tryptamines in industry, academia, research
and development, or other applications. Both quantitative and
qualitative information is sought.
Although information is requested for all tryptamine substances
regardless of substitutions, DEA is particularly interested in
tryptamines that meet one
[[Page 44315]]
or more of the following conditions: (a) Has a secondary or tertiary
amine formed by the substitution on the nitrogen atom of the 2-
aminoethyl chain by various alkyl groups, whether in chain or ring form
(for example, N-alkyltryptamine, N,N-dialkyltryptamine, N,N-
tetramethylenetryptamine), (b) has an alkyl substitution on the alpha
position of the 2-aminoethyl chain, and/or (c) has substituents on the
indole ring system, including, but not restricted to, various alkyl
chains, halogens, hydroxyl, alkoxy, acetyl, or alkylthio groups, at one
or more positions except the one (indole nitrogen) position. DEA is
especially interested in learning of the uses of the following
tryptamines.
2-alpha-dimethyltryptamine
4-hydroxy-N,N-diisopropyltryptamine
4-hydroxy-N,N-dipropyltryptamine
4-hydroxy-N,N-tetramethylenetryptamine
4-hydroxy-N-isopropyl-N-methyltryptamine
4-hydroxy-N-methyl-N-propyltryptamine
5,6-dimethoxy-N-isopropyl-N-methyltryptamine
5-methoxy-alpha,N-dimethyltryptamine
5-methoxy-alpha-methyltryptamine
5-methoxy-N,N-dimethyl-2-methyltryptamine
5-methoxy-N,N-dimethyltryptamine
5-methoxy-N,N-tetramethylenetryptamine
5-methoxy-N-methyltryptamine
6-methoxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline
7-methoxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline
9,10-didehydro-6-allyl-N,N-diethylergoline-8-beta-carboxamide
9,10-didehydro-6-propyl-N,N-diethylergoline-8-beta-carboxamide
9,10-didehydro-N,N,6-triethylergoline-8-beta-carboxamide
alpha,N-dimethyltryptamine
N,N-dibutyltryptamine
N,N-dibutyl-4-hydroxytryptamine
N,N-diethyl-2-methyltryptamine
4-hydroxy-N,N-diethyltryptamine
N,N-diethyl-5-methoxytryptamine
N,N-diisopropyl-4,5-methylenedioxytryptamine
N,N-diisopropyl-5,6-methylenedioxytryptamine
N,N-diisopropyltryptamine
N,N-dimethyl-2-methyltryptamine
N,N-dimethyl-4,5-methylenedioxytryptamine
N,N-dimethyl-4-hydroxytryptamine
N,N-dimethyl-5,6-methylenedioxytryptamine
N,N-dimethyl-5-methylthiotryptamine
N,N-dipropyltryptamine
N,N-tetramethylenetryptamine
N-butyl-N-methyltryptamine
N-ethyl-4-hydroxy-N-methyltryptamine
N-ethyl-N-isopropyltryptamine
N-ethyltryptamine
4-methoxy-N-methyl-N-isopropyltryptamine
5-methoxy-N-methyl-N-isopropyltryptamine
N-isopropyl-N-methyl-5,6-methylenedioxytryptamine
N-isopropyl-N-methyltryptamine
N-methyltryptamine
4-acetoxy-N-methyl-N-isopropyltryptamine
4-acetoxy-N,N-diisopropyltryptamine
4-acetoxy-N,N-dipropyltryptamine
4-acetoxy-N,N-diethyltryptamine
5-methoxy-N,N-diallyltryptamine
5-methoxy-N-monoallyltryptamine
5-methoxy-N-methyl-N-isopropyltryptamin
N-methyl-N-isopropyltryptamine
4-hydroxy-N,N-diethyltryptamine
5-methoxy-N,N-diethyltryptamine
Such information may be submitted to the Drug and Chemical
Evaluation Section and is requested by October 3, 2006. Information
designated as confidential or proprietary will be treated accordingly.
Confidential business information is protected from disclosure under
Exemption 4 of the Freedom of Information Act, 5 U.S.C. 552(b)(4)(FOIA)
and the Department of Justice procedures set forth in 28 CFR 16.8.
Dated: July 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control.
[FR Doc. E6-12599 Filed 8-3-06; 8:45 am]
BILLING CODE 4410-09-P
